Braincure is an early-stage research and development company focused on evaluating a novel approach to the treatment of Alzheimer s disease
Online PR News – 09-November-2015 – Braincure-Biotech.com today announced that the company has engaged Tsai Chiang, renowned pioneer in the field of neurology, entrepreneur and present President of Neurology Committee, as a special advisor. Mr. Chiang will serve as an invaluable resource in supporting rapid growth for the company as neurology stimulation, the focus of Braincures research, is formally launched for study in Asia, Europe and then the United States.
Braincure Biotech is focused on evaluating an approach to Alzheimer s disease treatment that has been clinically recognized, but never before studied in a clinically significant way. The potential impact on patients and their families is extremely significant, said Mr. Chiang. Serving as a special advisor to help drive corporate growth affords me yet another opportunity to reinforce the focus of serving others in a broad range of capacities as a public servant, as an entrepreneur and most recently, as President and CEO of a large Pharmaceutical conglomerate, where technology was applied to humanitarian purposes aswell.
Suhon Horng, president and CEO of Braincure Biotech stated, We couldnt be happier to have the benefit of Mr. Chiangs experience and expertise as the company moves into initial clinical trials for its neurological stimulation medical device in Asia. These outcomes have the potential to demonstrate that prior clinical observation and analysis of the effects of neurological stimulation on cognitive function in Alzheimer s disease patients is measurable and sustainable, and therefore offers hope for millions of people, and their families, where there was none before. With the Mr. Chiangs support and input we are working to move forward quickly and effectively.
About Braincure Biotech